Drug Trial Radar · NCT06285227
Study of CM313 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Oct 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
51
Planned (sponsor's estimate)
Start
Mar 12, 2024
Primary completion
Apr 30, 2025
Study completion Apr 30, 2025
Sponsor
- Lead sponsor
- Keymed Biosciences Co.LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single center, randomized, open/double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacokinetic characteristics, and immunogenicity of CM313 administered subcutaneously or intravenously at different doses in healthy male subjects.
Conditions
- Healthy
Interventions
CM313 injectionBiological
CM313
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventTime frame: Up to week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Fudan University
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.